ScrutarSign up free

CARDINAL HEALTH INC (CAH)

SEC filings, insider trading & institutional ownership from EDGAR.

NYSEHealth CareHealth Care Providers & Services

Cardinal Health, Inc. is a global healthcare services and products company that provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It supplies medical products and pharmaceuticals, along with solutions intended to make the healthcare system and supply chain more efficient and less costly.

The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals and over-the-counter healthcare and consumer products in the United States. It maintains prime vendor relationships, repackages generics and OTC products, provides pharmacy management services to hospitals, and operates a limited number of pharmacies. For manufacturers, it provides distribution, inventory management, data reporting, new product launch support, and chargeback administration. Its Specialty businesses distribute specialty pharmaceuticals (oncology, rheumatology, gastroenterology, urology, nephrology and others) and human-derived plasma products, and also provide consulting, patient support, group purchasing, and data analytics services. They support physician practices through management services organization (MSO) platforms. The segment earns margin from its generic program, from distribution services agreements with branded manufacturers, and from OTC products. Red Oak Sourcing, a generic sourcing venture with CVS Health, negotiates generic supply contracts for both companies through June 2029. The Global Medical Products and Distribution segment manufactures and sources Cardinal Health brand medical, surgical, and laboratory products. These include exam and surgical gloves, needles, syringes, sharps disposal, compression, incontinence, nutritional delivery, wound care, surgical drapes and gowns, fluid suction and collection, urology, and electrode products. It also distributes national brand products, assembles procedure kits, provides supply chain services in the U.S. and Canada, and offers the Wavemark inventory management platform. Other segments are Nuclear and Precision Health Solutions (nuclear pharmacies and radiopharmaceutical manufacturing, including Xofigo contract manufacturing and Lymphoseek), at-Home Solutions (Edgepark and ADS direct-to-patient supplies, plus a business-to-business at-Home distribution service), and OptiFreight Logistics (shipping and logistics for healthcare providers).

Customers include retail chain and independent drug stores, supermarket and mass merchandiser pharmacies, hospitals, specialty pharmacies, physician practices, dialysis clinics, laboratories, surgery centers, home medical equipment providers, home health and hospice agencies, e-commerce customers, and patients with chronic conditions. Cardinal Health brand products are sold in the United States, Canada, Europe, Asia, and other markets. CVS Health accounted for 28 percent of fiscal 2026 revenue and the five largest customers for 43 percent. Sales to members of the group purchasing organizations Vizient and Premier made up 29 percent of revenue. Recent acquisitions have expanded its specialty and MSO offerings, including Solaris Health, Urology America, GI Alliance, and Integrated Oncology Network, as well as ADS in home diabetes supplies.

The company relies on many suppliers. Its five largest suppliers accounted for 39 percent of fiscal 2026 revenue and the largest for about 13 percent. It operates in highly competitive markets, competing on price, service, product breadth, and quality. Pharma competitors include McKesson and Cencora, regional and specialty distributors, and third-party logistics companies. GMPD competitors include Medline and Owens & Minor and other diversified healthcare companies and distributors.

AI-summarized from Item 1 (Business) of the company’s most recent 10-K filing.

RevenueFY2026
$254.25B
▲ 14.2%YoY
Net incomeFY2026
$1.71B
▲ 9.8%YoY
Diluted EPSFY2026
$7.23
▲ 12.1%YoY
Gross margin
3.8%
▲ 17 bpsYoY
Insider net6 mo
+2.1K
shares8 sells0 buys
Institutions
56
$32.65B held

Financials

As reported to the SEC via XBRL, no adjustments

All financials →
Revenue & net income
$100B$200B$300B
FY2023FY2024FY2025FY2026
RevenueNet income
FY2026 highlightsfrom 10-K
Gross profit$9.77B
Operating income$2.61B
Diluted EPS$7.23
Gross margin3.8%
Net margin0.7%

Latest filings

10-K, 10-Q, 8-K, Form 4 & 13D/G. Sourced directly from SEC EDGAR

All filings →
FormFiledAccession
8-KNov 5, 2026EDGAR
10-QNov 5, 2026EDGAR
8-KOct 1, 2026EDGAR
DEF 14ASep 21, 2026EDGAR
4Scherer Mary C.Aug 20, 2026EDGAR
4Hollar Jason M.Aug 20, 2026EDGAR
4Mason Stephen MAug 20, 2026EDGAR
4WEITZMAN DEBORAHAug 20, 2026EDGAR

Insider trading

From Form 4 filings

All →
InsiderDateType
Scherer Mary C.Aug 19, 2026Sell
Hollar Jason M.Aug 19, 2026Sell
Greene Michelle D.Aug 18, 2026Sell
Mayer Jessica LAug 18, 2026Sell
Alt Aaron EAug 18, 2026Sell

Top holders

13F & 13D/G • latest quarter

All →
HolderStakeFiledValue
BlackRock, Inc.11.5%Aug 7, 2026$6.29B
Vanguard Capital Management6.6%Aug 13, 2026$3.63B
WELLINGTON MANAGEMENT GROUP LLP6.4%Aug 14, 2026$3.53B
Vanguard Portfolio Management5.9%Aug 13, 2026$3.26B
STATE STREET CORPORATION5.2%Sep 22, 2026$2.84B

CAH's filings are public. The insight is one click away.

Scrutar's AI reads every CAH filing and points out what matters. Red flags, risk shifts, disclosure quality and key relationships. Cited to the source, free with an account.

Analyze CAH filingsNo credit cardAI reports included on the free plan

Never miss a CAH filing.

Get an email when CAH files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.

Free foreverNo account requiredOne-click unsubscribe

Protected by reCAPTCHA. Privacy & Terms

Companies related to CAH

Peers identified from CAH's own SEC filings.

Data as of Nov 8, 2026Source: SEC EDGAR.